PressApril 23, 2025 Clearmind Medicine Launches First U.S. Clinical Site for its FDA-Approved Clinical Trial to Combat Alcoholism
PressApril 23, 2025 Psyence BioMed Announces USD$500,000 Follow-On Investment in PsyLabs and Global Ibogaine Supply Agreement
PressApril 23, 2025 MindMed Announces First Patient Dosed in Phase 3 Emerge Study of MM120 in Major Depressive Disorder (MDD)
PressApril 23, 2025 Clearmind Medicine Announces First U.S. Clinical Site Initiation for CMND-100 Clinical Trial in Patients with Alcohol Use Disorder
PressApril 23, 2025 Tryptamine Therapeutics to Launch Groundbreaking Trial for Binge Eating Disorder Treatment
PressApril 23, 2025 Filament Health Announces FDA Authorization Of Phase 2 Clinical Trial Studying PEX010, The Company’s Botanical Psilocybin Drug Candidate, In Opioid Use Disorder
PressApril 15, 2025 Algernon Pharmaceuticals Receives Notice of Allowance from European Patent Office for Repirinast for Kidney Disease
PressApril 15, 2025 Clearmind Medicine Announces the Publication of International Patent Application for Next-Gen Psychedelic Compounds to Treat Mental Health Disorders
PressApril 15, 2025 Psyence BioMed Signs LOI with Southern Star Research to Expand Phase IIb Clinical Trial in Australia
PressApril 3, 2025 Clearmind Launches its EDC System to Support its Phase I/II Clinical Trial of its MEAI-Based Treatment
PressApril 3, 2025 Corporate Update: Psyence Biomedical Ltd Redefines Psychedelic Medicine with a Multi-Asset Strategy, Advancing Clinical Trials and Scalable Manufacturing
PressApril 3, 2025 Filament Health Reports Q4 and Year End 2024 Financial Results and Operational Highlights
PressApril 3, 2025 Clearmind Medicine’s FDA-Approved Clinical Trial for CMND-100 Moves Forward as Drug Arrives in the U.S., Advancing Toward Key Milestones
